|Description||Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.|
|Brife Description||humanized monoclonal antibody, IL-5, asthma|
|Application||the treatment of severe asthma|
Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe ast...
CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation.
CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly throug...
The mesylate salt form of Apilimod. Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with ...
SU 5201 is an inhibitor of IL-2 production.
Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis...
Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.
Ladarixin is Interleukin 8A and Interleukin 8B receptor antagonist. IL-8A and IL-8B inhibition blocks and reverses type 1 diabetes in mice. In Dec 2015, Phase-I...